Neonatal hyperbilirubinemia (NHB) is one of the most common problems encountered in newborn. While some cases are harmless many cases can be quite severe and lead to neurotoxicity or even death. The wide variety of NHBs outcomes is, in part, due to the different number of causes the disease has.  One of the hemolytic causes of NHB is Glucose-6-phosphate dehydrogenase deficiency (G6PDD), which is common in Asia, some studies show between 15 and 20% of males have the X linked deficiency.  The onset or progression of NHB can be triggered by the administration of certain antibiotics with hemolytic properties in patients with G6PDD. Therefore, it is imperative to first determine the G6PD status of the patient before administration of any antibiotics. This is currently done via a comparative lab assay, but recently a G6P biosensor has been developed, while it has only been tested on adults the device needs be validated in newborns.  If successfully validated, the biosensor would be able to be used by midwives and nurses in the delivery room. Saving shipping and lab processing time, which reduces the time that potentially beneficial treatments can be administered.